The US ordinarily produces 98% of the infant formula it uses, with imported formula primarily coming from Mexico, Ireland and the Netherlands, the agency said in a statement. But because of the shortage, the FDA is outlining a process by which it “would not object to the importation of certain infant formula products intended for a foreign market,” as well as the US distribution of products that were made domestically for export to others countries.
“Companies seeking to take advantage of these flexibilities should submit information for the FDA to quickly evaluate whether the product can be used safely and whether it provides adequate nutrition,” the agency said. “For example, labeling, information on nutritional adequacy and safety testing, and information about facility inspection history.”
The agency said it is already in discussions with some manufacturers and suppliers regarding additional supply.
FDA Commissioner Dr. Robert Califf said in a statement: “With these flexibilities in place, we anticipate that those products that can quickly meet safety and nutrition standards could hit US stores in a matter of weeks.”
“The White House is having ongoing conversations with the four major infant formula manufacturers — Reckitt, Abbott, Nestle/Gerber, and Perrigo — to work with them to identify transportation, logistical, and supplier hurdles to increasing production of formula at their US – and FDA-approved facilities, to expand the amount and speed of FDA-approved formula being shipped into the country, and ensure that formula is quickly moving to retailers from factories,” the White House official said.
There are also efforts to shore up the supply chain, with outreach to formula manufacturers’ suppliers.
“We are also contacting suppliers to infant formula manufacturers to inform them that their materials are critical for boosting US infant formula production and they should prioritize their production and delivery,” the official noted.
During an appearance on CNN’s “New Day” on Monday, US Food and Drug Administration commissioner Dr. Robert Califf said the administration is “doing everything we can” to resolve the shortage.
Califf pointed to efforts to work with manufacturers to increase production, work on supply chain, work closely with Abbott to get its shuttered plant open as soon as possible.
Pressed on how much of an effect the move to make it easier to import some formulas will have, he said the situation more broadly will “gradually improve” over a “few weeks.” This Thursday, Califf certifies before the Agriculture Appropriations Subcommittee on the FDA’s 2023 budget request and oversight of infant formula.
The baby formula shortage has been exacerbated by the FDA’s shutdown of the country’s largest formula plant, the Abbott Nutrition facility in Sturgis, Michigan.
Pressed on how soon supply will be back to normal, HHS Secretary Xavier Becerra declined to give specifics, saying on CNN Monday that “Abbott is the one that can tell you the timeline.”
Becerra said the federal government is working with the company to make sure it’s addressing the safety concerns raised to them and that “it should be done in a matter of weeks.”
“We don’t run their plants. Only they can address the safety concerns that were identified through our inspections. They have been working on this while, we have been advising them of what they need to do,” Becerra told CNN’s Kate Bolduan on “At This Hour.”
“We’ll do everything we can, we’ll pull all the levers we can to help them move as quickly as possible, but they control their plant. They own and operate it, they’re the ones that have to do the fix. “
Abbott said last week it could restart production at its Michigan facility, pending FDA approval, within two weeks, but it could be a few more weeks until the formula is made available on shelves.
On CNN, Becerra also defended the administration’s response to the Abbott recall and complaint, saying, “We have been moving as quickly as we can.”
“FDA moves with deliberate speed to make sure that if you’re going to do something as drastic as urge a manufacturer to pull a product off the shelves, that there’s good evidence for it. That’s why it takes a little time,” he said .
This story has been updated with additional reporting.
CNN’s Brenda Goodman and Jacqueline Howard contributed to this report.